BioNTech SE (BNTX) Consolidated Net Income (2018 - 2025)
BioNTech SE (BNTX) reported Consolidated Net Income of -$174.4 million for Q4 2025, down 147.59% on a YoY basis from $366.4 million in Q4 2024, and down 290.98% sequentially from $91.3 million in Q3 2025.
BioNTech SE (BNTX) Consolidated Net Income (2018 - 2025) Analysis & Trends
BioNTech SE (BNTX) has 8 years of Consolidated Net Income data on file, last reported at -$174.4 million in Q4 2025.
- For the quarter ending Q4 2025, Consolidated Net Income fell 147.59% year-over-year to -$174.4 million; the trailing twelve-month figure through Dec 2025 stood at -$1.1 billion (down 41.52% YoY), and the FY2025 full-year result was -$1.1 billion, down 47.92% from the prior year.
- Consolidated Net Income slipped to -$174.4 million in Q4 2025, from $91.3 million in the prior quarter.
- In the past five years, Consolidated Net Income ranged from a high of $7.2 billion in Q3 2021 to a low of -$865.6 million in Q2 2024.
- A 5-year average of $2.0 billion and a median of $650.4 million in 2024 frame the typical range for Consolidated Net Income.
- Across the five-year window, Consolidated Net Income soared 13561718996.32% in 2021 and tumbled 147.59% in 2025, its largest moves.
- Tracing BNTX's Consolidated Net Income over 5 years: stood at $7.2 billion in 2021, then tumbled by 42.08% to $4.1 billion in 2022, then plunged by 77.48% to $934.5 million in 2023, then sank by 60.79% to $366.4 million in 2024, then plunged by 147.59% to -$174.4 million in 2025.
- Business Quant data shows BNTX's Consolidated Net Income at -$174.4 million in Q4 2025, $91.3 million in Q3 2025, and -$474.1 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | BioNTech SE | 22.13 Bn | 22.13 Bn | 668.28 Mn | -174.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -174.37 Mn |
| Sep 30, 2025 | 91.30 Mn |
| Jun 30, 2025 | -474.06 Mn |
| Mar 31, 2025 | -499.65 Mn |
| Dec 31, 2024 | 366.42 Mn |
| Sep 30, 2024 | 131.02 Mn |
| Jun 30, 2024 | -865.60 Mn |
| Mar 31, 2024 | -378.60 Mn |
| Dec 31, 2023 | 934.45 Mn |
| Sep 30, 2023 | 320.26 Mn |
| Jun 30, 2023 | -690.38 Mn |
| Mar 31, 2023 | 980.18 Mn |
| Dec 31, 2022 | 4.15 Bn |
| Sep 30, 2022 | 3.13 Bn |
| Jun 30, 2022 | 3.17 Bn |
| Mar 31, 2022 | 7.11 Bn |
| Dec 31, 2021 | 7.16 Bn |
| Sep 30, 2021 | 7.22 Bn |
| Jun 30, 2021 | 6.33 Bn |
| Mar 31, 2021 | 2.60 Bn |